H.C. Wainwright raises Kodiak Sciences stock target to USD 126.00

Published on 10/17/2026 at 22:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Earnings are due November 12, 2026. Kodiak Sciences stock was USD 85.75 on October 16, 2026, down 2.69 percent versus Nasdaq close.

Analyst target and reporting date

H.C. Wainwright set a USD 126.00 target for Kodiak Sciences on October 12, 2026.
Gekko lists November 12, 2026 as Kodiak Sciences' next earnings date.
Kodiak Sciences stock closed at USD 85.75 on October 16, 2026, down 2.69 percent versus the Nasdaq prior close of USD 88.12.
Kodiak Sciences had a USD 5.4 billion market capitalization as of October 17, 2026.

KOD, US50015M1099, Illustration mit AI erstellt.

MarketBeat reported that H.C. Wainwright raised its Kodiak Sciences target from USD 96.00 to USD 126.00 in a research note issued on October 12, 2026, while maintaining a Buy rating. The target stood 46.94 percent above Kodiak's Nasdaq closing price of USD 85.75 on October 16, 2026. Kodiak Sciences stock closed down 2.69 percent from USD 88.12.

The next report is November 12

The next scheduled earnings date is November 12, 2026, according to Gekko. The date gives the market a defined checkpoint after a period of unusually large price swings. Kodiak reported no revenue in the trailing twelve months, while its clinical pipeline remains focused on retinal diseases.

Price remains below USD 104.00

At USD 85.75, the stock was 17.55 percent below its 52-week high of USD 104.00 and USD 74.81 above its 52-week low of USD 10.94. The October 16 session volume was 1,122,131 shares against an average volume of 1,658,553 shares.

The company has a USD 5.4 billion market capitalization, a negative price-to-earnings ratio of 20.47 and no dividend yield as of October 17, 2026. Kodiak's investor-relations page identifies the company as Nasdaq-listed under KOD and describes it as a precommercial biotechnology company developing retinal medicines through its Antibody Biopolymer Conjugate platform, according to Kodiak Sciences.

Comparison with peers

Kodiak Sciences (Nasdaq, USD): minus 2.69 percent, P/E minus 20.47, market capitalization USD 5.4 billion
Regeneron Pharmaceuticals (Nasdaq, USD): minus 0.70 percent, P/E 19.56, market capitalization USD 81.4 billion
Apellis Pharmaceuticals (Nasdaq, USD): P/E 38.71, market capitalization USD 5.3 billion

The closing level sets the frame

For investors, the central tension is the gap between Kodiak's USD 85.75 closing level and the USD 126.00 H.C. Wainwright target, alongside a calendar date that could reset expectations. The 52-week range also places the stock well below its recent high, despite the company's multi-stage retina pipeline.

Market context: Market report Nasdaq Composite.

More news and analyses on Kodiak Sciences stock